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from http://www.springer.com/series/8901.flows through a nasal cannula).Background
Oxygen therapy is the first step in the prevention and
treatment of hypoxemic respiratory failure and has trad-
itionally been delivered using nasal prongs or masks.
However, the maximal flow rates that these devices can
deliver are limited because of the discomfort generated
secondary to insufficient heat and humidity provided to
the gas administered. Although high‐flow oxygen ther-
apy is currently defined as flows greater than 30 l/min, it
is accepted that flows up to 15 l/min can be delivered
using conventional nasal prongs or masks; this flow is
far less than the peak inspiratory flow of a patient with
dyspnea. In addition, flows exceeding 6 l/min can lead to
insufficient humidification provided to the nasal mucosa,
even when a cold bubble humidifier is used. Therefore,
room air dilutes the supplemental oxygen, resulting in a
significant decrease in the fraction of the inspired
oxygen (FiO2) that finally reaches the alveoli.
In recent years, new devices that deliver totally condi-
tioned gas (37 °C containing 44 mg H2O/l [100% relative
humidity] using a heated humidifier and a heated inspira-
tory circuit) through a wide bore nasal cannula at very
high flow (up to 60 l/min) at a predetermined constant
oxygen concentration (21 to 100%) have emerged as a safe
and useful supportive therapy in many clinical situations.* Correspondence: ghernandezm@telefonica.net
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© 2017 Hernández et al.High‐flow nasal cannula (HFNC) supportive therapy
exerts its potential benefits through a variety of
mechanisms. In the literature this treatment strategy
has been variously described as nasal high flow and
high flow oxygen therapy, but we believe that the
most appropriate term is heated and humidified
HFNC supportive therapy. This term reflects the
features that generate the technique’s clinical effects
(i. e., the delivery of warm and humidified air at highNew insights
Physiological effects and consequences
Heated and humidified oxygen
Inhaling dry and cold oxygen provokes upper airway
dryness frequently leading to intolerance, and potentially
impairing mucociliary functions, such as secretion clear-
ance and airway defense. Results of studies demonstrate
that HFNC reduces patient discomfort and upper airway
dryness, although a potentially protective effect on
mucociliary function requires further investigation.
Another way in which HFNC improves extubation out-
come and weaning is by conditioning the inspired gas.
Various studies have demonstrated that HFNC improves
the management of respiratory secretions and reported
fewer reintubations secondary to upper airway obstruc-
tion and accelerated weaning in tracheostomy patients.
These findings support the idea that gas conditioning
probably alleviates inflammation of the tracheal mucosa
after transglottic intubation, and a protocol that includes
the use of HFNC prior to extubation, thereby preventing
the administration of dry and cold air in the native
airway of the patients, reinforces this approach [1].Carbon dioxide clearance
There is still not much information about the role of
HFNC in managing hypercapnia, except for the mech-
anism of dead‐space washout. By providing a high
flow of fresh air during expiration, HFNC may be
able to more rapidly washout the carbon dioxide
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constructed an airway model using a computed tom-
ography (CT) scan, and analyzed the lavage of gas
tracers under apneic conditions. The authors observed
a linear positive correlation between tracer‐gas clear-
ance in the model and the flow rate of HFNC, ap-
proximately 1.8 ml/s increase in clearance for every
1.0 l/min increase in flow [2].
However, in recent years, new studies have highlighted
some additional mechanisms affecting CO2 clearance.
Alveolar ventilation has been suggested by Patel et al.,
after obtaining a mean apnea time of 17 min in surgical
patients [3]. The authors reported further evidence that
classical apneic oxygenation provided little clearance of
CO2 apart from that obtained from limiting rebreathing.
Continuous insufflation of a high‐flow gas mixture facili-
tates oxygenation and CO2 clearance through gaseous
mixing. Evidence for the existence of flow‐dependent,
non‐rhythmic ventilatory exchange can be provided by
comparing the increase in rise of CO2 under different
continuous insufflation apneic conditions. While Rudolf
and Hohenhorst [4] reported a rate of carbon dioxide
increase of 0.24 kPa/min using a low‐flow oxygen intra-
tracheal cannula (0.5 l/min), Patel et al. [3] achieved a
rate of carbon dioxide increase of 0.15 kPa/min and a
steady‐state carbon dioxide level was not reached. This
result was improved only when using a high‐flow
oxygen intratracheal cannula (45 l/min), reaching a
steady‐state carbon dioxide level within 5 min of the
start of the apnea [4].
Recently, Hernandez et al. [5] reported data support-
ing a possible role of HFNC in managing hypercapnia
after extubation. The investigators compared non‐inva-
sive ventilation (NIV) to HFNC in a fixed 24 h protocol
after extubation in high‐risk for reintubation patients,
using a non‐inferiority randomized trial. There was a
trend towards a higher rates of postextubation respira-
tory failure due to hypercapnia in the NIV group than in
the HFNC group, although this difference was not trans-
lated to the rates of hypercapnia as the reason for reintu-
bation. They argued that the real time under NIV, clearly
inferior to the 24 h expected by protocol, suggests that
discomfort could have been the reason for hypercapnic
postextubation respiratory failure in some NIV patients,
as PaCO2 improved without any respiratory support in
most patients. The reported rates of reintubation due to
hypercapnia were similar in the two groups, as were the
values of gasometric variables at reintubation, suggesting
that high‐flow is at least as good as NIV for managing
postextubation hypercapnia in high‐risk patients.
Positive pharyngeal pressure
HFNC can induce a positive pharyngeal pressure during
expiration due to its constant ingoing flow, with theeffect mainly determined by the flow rate provided by
HFNC and the expiratory flow exhaled by the patient,
with lower pressures when the patient keeps the
mouth open.
Parke and McGuinness [6] reported that HFNC in-
creased the mean pharyngeal pressure by about 1
cmH2O per 10 l/min, within a range of 30–50 l/min, but
more recently [7], the same group reported that the lin-
ear increase in the pharyngeal pressure was maintained
when using extra high‐flow with 100 l/min (combining
two HFNC systems), obtaining pharyngeal pressures up
to 11.9 cmH2O. However, these values were obtained in
healthy volunteers and extrapolation to the critical care
arena may not be accurate.
Despite this uncertainty about how much positive end‐
expiratory pressure (PEEP) can really be offered by
HFNC, studies [8] have demonstrated that end‐expira-
tory lung impedance increases with rising flow rate of
HFNC, suggesting an increase in end‐expiratory lung
volume. In addition, hemodynamic changes similar to
those obtained in patients under NIV with pressure
levels close to 10 cmH2O have been reported [9]. Right
atrial pressure has been considered as a surrogate of
right ventricular preload and is most commonly esti-
mated by inferior vena cava (IVC) diameter and the
presence of inspiratory collapse. Changes in IVC diam-
eter have been used to determine preload responsiveness
in positive pressure ventilated patients. In a population
of patients with New York Heart Association (NYHA)
class III heart failure, treatment with HFNC at 20 and
40 l/min was associated with mean attributable reduc-
tions in the IVC inspiratory collapse of 20 and 53% from
baseline, respectively. These changes were reversible
after HFNC withdrawal suggesting that HFNC therapy
may modify the hemodynamic status in heart failure pa-
tients at the same rate as does NIV.
HFNC is, therefore, not entirely similar to applying
continuous positive airway pressure (CPAP), which
aims to maintain a steady level of positive pressure
during the whole cycle of breath. The target of HFNC
is flow instead of pressure, so the objective when ap-
plying HFNC should not be the pharyngeal pressure
measured but the changes in hemodynamic status
and the increase in lung aeration.Clinical data
Acute hypoxemic respiratory failure
Effects of HFNC on physiological variables and comfort
The first studies in patients with acute respiratory failure
focused on the effects of HFNC therapy on physiological
variables [10–12] and reported oxygenation enhance-
ment with reductions in respiratory rate and no changes
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Hernández et al. Critical Care  (2017) 21:62 Page 6 of 11better tolerated and achieved a greater level of comfort
than conventional oxygen devices [10, 12]. HFNC was
also usually better tolerated than NIV, although NIV ob-
tained greater improvements in oxygenation [13, 14].
In addition, HFNC has been used in small cohorts of
patients with acute respiratory failure in the emergency
department [15, 16] and even in 150 children less than 2
years old during interhospital transport [17]. The effects
on oxygenation and rates of intubation reported in all
these studies are similar to those found when HFNC has
been used in patients with acute respiratory failure
admitted to critical care areas, suggesting that, with
adequate monitoring, HFNC can be safely used outside
the critical care setting.
Effects on intubation rate and mortality
These physiological studies provide the rationale for
considering HFNC as a potentially useful tool for de-
creasing intubation rates and mortality in patients with
acute respiratory failure. The first randomized controlled
trial (RCT) included postoperative cardiac surgery pa-
tients with mild to moderate acute respiratory failure
[18]. In that preliminary trial, HFNC patients were less
likely to need escalation to NIV and had fewer desatura-
tions than those treated using a standard humidified
high flow face mask. In another retrospective analysis of
a prospectively assessed cohort of 37 lung transplant pa-
tients readmitted to the ICU because of acute respira-
tory failure, HFNC therapy was the only variable at ICU
admission associated with a decreased risk of mechanical
ventilation in the multivariate analysis [19]. The absolute
risk reduction for mechanical ventilation with HFNC
was 29.8%, and only three patients needed to be treated
with HFNC to prevent one intubation. Moreover, non‐
ventilated patients had an increased survival rate.
More recently, the results of the first large RCT to as-
sess clinical outcomes with HFNC (50 l/min), conven-
tional oxygen devices and NIV have been published [20].
The study included 310 patients with de novo hypoxemic
acute respiratory failure, defined as PaO2/FiO2 ratio ≤ 300
mmHg or respiratory rate > 25 bpm with 10 lpm of O2.
Patients with a history of chronic respiratory disease, in-
cluding chronic obstructive pulmonary disease (COPD),
as well as patients with acute cardiogenic pulmonary
edema, severe neutropenia and hypercapnia (PaCO2 > 45
mmHg) were excluded, as were patients with other organ
failures, including hemodynamic instability or vasopres-
sors at the time of inclusion. The most frequent cause of
acute respiratory failure was pneumonia (75%) and 80% of
the enrolled patients showed bilateral pulmonary infil-
trates at study inclusion. The primary outcome (the rate
of endotracheal intubation) did not differ significantly be-
tween the groups (HFNC 38% vs. standard oxygen 47%
and NIV 50%; p = 0.18).This negative result may be due to the fact that the
observed rate of intubation with standard oxygen was
lower than expected and, therefore, the study may have
been underpowered. However, a post hoc adjusted ana-
lysis including the 238 patients with a PaO2/FiO2 ratio ≤
200 mmHg found that HFNC reduced intubation rates
(p = 0.009). In the entire cohort, HFNC increased venti-
lator‐free days, reduced 90‐day mortality and was associ-
ated with better comfort and lower dyspnea severity. In
contrast, NIV patients had higher 90‐day mortality rates
than HFNC patients.
Mechanisms that may explain these findings are the
small amount of positive airway pressure and increased
CO2 excretion with HFNC, the overall reduction in the
need for intubation and the lower incidence of septic
shock. Moreover, important concerns have been raised
regarding how NIV was applied. First, half of the
patients in the NIV group were treated with NIV for
less than eight hours during the first two days of
randomization and received HFNC between NIV
sessions. Second, high tidal volumes (9.2 ± 3.0 ml/kg)
were used, which may have aggravated the preexisting
lung injury. In fact, patients with acute respiratory
failure usually have high respiratory rates and minute
volumes and are more likely to present patient‐ventila-
tor asynchronies. Third, relatively low levels of PEEP
were used in potentially recruitable patients (5 ± 1
cmH2O). Fourth, intermittent sessions of NIV may in-
duce the phenomenon of recruitment/derecruitment,
generating ventilator‐induced lung injury (VILI). Fi-
nally, NIV was delivered through a face mask although
it has later been shown that a helmet interface may be
associated with better outcomes [21, 22]. Thus, the
NIV protocol in this study could be assumed to be
close to what is real practice at the bedside in many
centers treating acute respiratory failure with NIV, so
an underestimation of the NIV treatment effect in a
pragmatic trial cannot be ruled out.
More recently, a post hoc subgroup analysis in a sub-
set of immunocompromised patients was performed on
the FLORALI study [23]. Thirty patients treated with
standard oxygen therapy, 26 treated with HFNC, and
26 treated with NIV were included. The intubation and
mortality rates were significantly higher in patients ran-
domly assigned to NIV and, apart from age, the use of
NIV as the first‐line therapy was the only variable inde-
pendently associated with a higher risk of endotracheal
intubation and mortality in the multivariate logistic re-
gression analysis. Moreover, the expired tidal volume
measured 1 h after NIV initiation was higher in the
patients who died than in survivors (11.1 ± 2.6 ml/kg of
predicted weight versus 7.6 ± 3.1 ml/kg; p = 0.02).
Similarly, higher tidal volumes have been associated
with NIV failure [24].
Hernández et al. Critical Care  (2017) 21:62 Page 7 of 11Thus, the high tidal volumes and high transpulmonary
pressures obtained during NIV may induce VILI in a
pre‐injured lung and may be at least partially responsible
for NIV failure and higher mortality. These results were
similar to those observed in a recently published 8‐year
observational study of a cohort of 115 immunocom-
promised patients [25].
Two recent systematic reviews and meta‐analyses have
also been published that evaluated the effectiveness of
HFNC [26, 27]. In the first study, no differences in terms
of mortality or higher respiratory support requirement
was observed [26]. Most recently, Monro‐Somerville
et al. [27] found that, although HFNC appears to be well
tolerated, no difference in intubation rates or mortality
was observed in patients treated with HFNC compared
to those treated with usual care (conventional oxygen or
NIV). However, the required information size was not
reached: in fact, only 30.6 and 62.3% of the estimated
needed patients were included for the primary (mortal-
ity) and secondary (intubation) outcomes, respectively.
Moreover, HFNC was shown to have better survival and
lower intubation rates than conventional oxygen and,
although no differences were observed compared with
NIV, HFNC was better tolerated. Finally, certain meth-
odological issues regarding some of the studies included
in both meta‐analyses should be noted. First, a study by
Stephan et al. [28] was a positive non‐inferiority trial
comparing HFNC and NIV; however, in the meta‐ana-
lysis it appears as a negative trial as no differences were
observed between HFNC and NIV. Second, in a study
by Lemiale et al. [29], HFNC was only used for a 2 h‐
trial and in such a short period of time it would be diffi-
cult to observe any difference between treatments.
Finally, and most importantly, studies included in both
meta‐analyses had very heterogeneous populations of
acute respiratory failure patients in terms of severity
with huge differences in risks of intubation.
Predictors of HFNC success
The existence of accurate, early predictors of HFNC suc-
cess is important. Indeed, a recent propensity‐score ana-
lysis associated early intubation (within the first 48 h)
with better ICU survival [30]. In spite of its limitations,
the study by Kang et al. [30] raises an important issue –
the fact that delayed intubation may worsen the progno-
sis of patients treated with HFNC. Therefore, the ability
to describe accurate predictors of HFNC success that
can allow timely endotracheal intubation in patients who
are likely to fail is a point of special interest. Sztrymf
et al. [12] reported that respiratory rate as well as the
percentage of patients exhibiting thoraco‐abdominal
asynchrony as early as 30 and 15 min after the beginning
of HFNC were significantly higher in patients who re-
quired endotracheal intubation. Moreover, the PaO2/FiO2 ratio 1 h after the start of HFNC was significantly
lower in patients requiring invasive mechanical ventila-
tion. Similarly, in a series of 20 patients with H1N1 infec-
tion treated with HFNC, worse PaO2/FiO2 ratios were
observed in patients who required intubation after six
hours of treatment [31]. Interestingly, a recent
prospective study showed that patients with severe
pneumonia who had a ROX index (defined as the ratio
of SpO2/FiO2 to respiratory rate) ≥ 4.88 after 12 h of
HFNC therapy were less likely to be intubated, even
after adjusting for potential covariates [32]. Moreover,
among patients who were still on HFNC after 18 h, the
median change in the ROX index between 18 and 12 h
was significantly higher in patients who did not require
intubation. However, non‐pulmonary severity has also
been described as a good predictor of HFNC failure.
Indeed, the presence of shock has been associated with a
higher risk of mechanical ventilation [19, 23].
In a preliminary study by Hernandez et al. [33] titrat-
ing high‐flow according to patient tolerance, a gas flow >
35 l/min 12 h after extubation predicted reintubation,
suggesting that the flow tolerated by patients is a marker
of severity; unfortunately, this result was not reproduced
in the subsequent randomized trial [5].ARDS patients
Another controversial issue is whether patients with bi-
lateral infiltrates treated with HFNC can be considered
as having acute respiratory distress syndrome (ARDS).
In fact, most patients included in studies have bilateral
infiltrates [20, 32]. The Berlin definition of ARDS [34]
requires a minimum of 5 cmH2O of PEEP, and it has
been shown that HFNC can provide a level of PEEP that
is higher at peak expiratory pressure [7]. Moreover,
ARDS does not begin at the time of mechanical
ventilation onset. Therefore, it can be accepted that
patients with a risk factor for ARDS, who are hypox-
emic (PaO2/FiO2 ratio ≤ 300 mmHg) and have bilat-
eral infiltrates not fully explained by cardiac failure or
fluid overload, may be considered as ARDS patients.
In these patients, HFNC may achieve success rates
similar to those of NIV [35].Prevention of postextubation respiratory failure and
reintubation
Extubation failure is an independent predictor of mortal-
ity. The development of therapies to prevent this has
been focused on specific causes of reintubation (corti-
coids for larynx edema and NIV for hypercapnic respira-
tory failure in patients with chronic pulmonary diseases)
and in patients with risk factors associated with extuba-
tion failure. Usually, extubated patients receive conven-
tional oxygen therapy for correcting the oxygenation
Hernández et al. Critical Care  (2017) 21:62 Page 8 of 11impairment. This system provides low flow and does not
guarantee the FiO2.
Low‐risk‐of‐reintubation patients
Two preliminary physiological studies comparing HFNC
with conventional oxygen devices using a crossover de-
sign and during a short period of time after extubation
have confirmed the consistent benefit of HFNC in terms
of overall comfort. Rittayamai et al. [15] observed a de-
crease in respiratory rate and heart rate when comparing
HFNC therapy at 35 l/min vs conventional oxygen de-
vices at 6–10 l/min in 17 patients during a 30 min
period. In contrast, Tiruvoipati et al. [36] found no
change in these physiological variables when comparing
30 l/min delivered through HFNC or 15 l/min through a
high flow face mask. Shortly after this study, the first RCT
comparing HFNC with conventional oxygen devices after
extubation was published [37]. The study included pa-
tients with acute respiratory failure due to pneumonia and
trauma who were mechanically ventilated for a mean of
almost five days before extubation. In these patients, the
use of HFNC was associated with better comfort, better
oxygenation, fewer desaturations and interface displace-
ments, and a lower reintubation rate.
Postoperative patients remain an important subgroup
of patients with some differences related to the response
to HFNC. The effectiveness of HFNC therapy during the
extubation period in postoperative patients remains
controversial; most studies on this issue have included
patients after cardiothoracic surgery. Parke et al. [38]
included a non‐selected population of cardiac surgery
patients with mild to moderate acute respiratory failure,
observing that HFNC patients more frequently suc-
ceeded and could be weaned to conventional oxygen
devices. In contrast, in patients randomized to conven-
tional oxygen devices, acute respiratory failure was more
likely to worsen and escalation to NIV or HFNC re-
quired. Corley et al. [39] included a population of car-
diac surgery patients with body mass index (BMI) ≥ 30
who were randomly assigned to prophylactic HFNC
therapy or conventional oxygen devices after extubation.
The authors did not observe any difference in atelectasis
formation, oxygenation, respiratory rate, or dyspnea.
Finally, the BiPOP study [28], a multicenter, non‐infer-
iority RCT, compared HFNC and NIV for preventing or
resolving acute respiratory failure after cardiothoracic
surgery. Three different types of patient were eligible:
patients who failed after a spontaneous breathing trial;
patients who succeeded but had a preexisting risk factor
for postoperative acute respiratory failure (BMI > 30, left
ventricular ejection fraction < 40%, and failure of previ-
ous extubation); and patients who succeeded after a
spontaneous breathing trial but then failed extubation
(defined as at least one of the following: PaO2/FiO2 <300, respiratory rate > 25 bpm for at least 2 h, and use of
accessory respiratory muscles or paradoxical respir-
ation). After randomizing more than 800 patients,
HFNC therapy did not increase the rate of treatment
failure (defined as reintubation, switch to the other study
treatment, or premature treatment discontinuation at
the patient’s request or due to an adverse event). There-
fore, as HFNC therapy did not worsen outcomes, may
be easier to administer, and requires lower nursing
workload, the authors concluded that the results sup-
ported the use of HFNC in this subset of patients.
Certain questions remain unanswered, however, such as
the optimal flow and the subset of patients who would
benefit the most from HFNC therapy.
Recently, Hernandez et al. [1] reported a multicenter
randomized trial analyzing the effect of HFNC compared
to conventional oxygen therapy in a population of low‐
risk‐of‐reintubation patients. In the study, the authors
aimed to evaluate whether high flow oxygen therapy
after planned extubation would reduce the need for rein-
tubation compared with standard oxygen therapy. The
all‐cause reintubation within 72 h was lower in the high
flow group (4.9 vs 12.2%). This difference was mainly
attributable to a lower incidence of respiratory‐related
reintubations in the high flow group (1.5% vs 8.7%).
The main benefit was observed on reducing reintuba-
tion secondary to hypoxemia and inability to clear se-
cretions. These results agree with those obtained by
Maggiore et al. [37].
The authors classified patients according to the criteria
for risk of reintubation. They did not use the type of re-
spiratory failure considering that the aim was to obtain
the preventive effects of HFNC and not treatment once
the failure was present. It is currently unclear how to
identify at risk patients for extubation failure. Previous
trials, like that of Thille et al. [40], have tried to identify
the underlying risks of extubation outcome. In keeping
with these studies, this trial included 10 risk factors,
which can clearly select a low risk population.
High‐risk‐of‐reintubation patients
Simultaneously, Hernandez et al. [5] compared HFNC
with NIV in patients at high risk for reintubation in a
non‐inferiority trial. While studies have suggested that
prophylactic NIV could prevent postextubation re-
spiratory failure, they appear inconsistent with regard
to reintubation. However, Thille et al. [40] added new
data supporting the benefit of NIV for this indication.
In a general population of critical patients use of NIV
has not been proved, for that reason in the low‐risk
group HFNC was compared to conventional oxygen
therapy [1].
This study confirmed that the reintubation rate was
non‐inferior in the HFNC group compared to the NIV
Hernández et al. Critical Care  (2017) 21:62 Page 9 of 11group within 72 h (22.8% vs 19.1%). For postextubation
respiratory failure, the authors reported a lower rate in
the HFNC group compared to the NIV group (26.9% vs
39.8%), suggesting that the postextubation respiratory
failure rate could be even higher in the NIV group. This
surprising result was explained by the significantly
higher adverse event rate in the NIV group (43% vs 0%),
mainly discomfort and subsequent early withdrawal of
the therapy (mean real time under NIV 14 h, instead of
the 24 h per protocol). This increased postextubation re-
spiratory failure rate was not correlated with the reintu-
bation rate, supporting a possible role of discomfort in
NIV patients as the reason for the postextubation re-
spiratory failure. In addition, the length of hospital stay
was significantly reduced in the HFNC group [5].Facilitating weaning in tracheostomized patients
Weaning of tracheostomy patients is still a challenge. To
our knowledge, only one randomized trial has included
high flow therapy in the protocol [41]. This was a single‐
center study including 181 critically ill tracheostomy
patients who were randomized to have the tracheal cuff
deflated or not during spontaneous breathing trials. All
patients received high‐flow conditioned oxygen therapy
through a direct tracheostomy connection to the max-
imum tolerated flow and conditioned up to 37 °C. Al-
though that study was not specifically designed to assess
the effectiveness of high flow through the trachea, the au-
thors hypothesized that HFNC therapy may have some
benefits in the weaning process of tracheostomy patients
with a deflated tracheal cuff. Positive airway pressure may
theoretically reduce microaspiration and, with a deflated
cuff, a higher flow is conveyed through the pericannular
space, allowing for better drainage of secretions.Improving performance
Regarding the methodology used in the protocol by
Hernandez et al. [1], HFNC was applied before extuba-
tion to prevent the entrance of dry and cold air into the
patient’s native airway from the start of treatment.
Although this is speculative, it could play a major role in
the early benefit that was found in the lower rate of
upper airway obstruction (laryngeal edema requiring
reintubation was not observed in the HFNC group).
Flow was titrated according to patient tolerance; initially
set at 10 l/min and titrated upward in 5 l/min steps until
patients experienced discomfort. Twelve hours after extu-
bation, a steady state is usually obtained. In that low‐risk‐
of‐reintubation study, authors observed a tolerated main
gas flow of 31 l/min, a moderate flow as compared to the
main flow tolerated in the high‐risk‐of‐reintubation study
(50 l/min), reinforcing the idea that under these condi-
tions the flow tolerated is a marker of severity.Another point of the protocol used by Hernandez
et al. [1] deserves mention: patients who tolerated the
spontaneous breathing trial were reconnected with the
previous ventilator settings for rest and clinical evalu-
ation of airway patency. Some preliminary studies sug-
gest that spontaneous breathing trials could lead to mild
respiratory muscle fatigue that could somehow influence
extubation success. However, clinical evidence support-
ing this hypothesis is lacking.
After 24 h, high‐flow therapy was stopped and, if neces-
sary, patients received conventional oxygen therapy.
Maggiore et al. [37] reported better results using high‐flow
for 48 h after extubation, with some of the variables show-
ing significant improvement after 24 continuous hours of
application, suggesting that some time‐dependent effects
could lead to improved performance of this therapy.
With this information in mind, clinicians should coun-
terbalance efficacy and safety. On the one hand, the longer
the duration of HFNC application, the greater the clinical
efficacy. On the other hand, the longer the duration of
HFNC, the greater the probability of delaying escalation of
respiratory support when HFNC fails. In fact, as suggested
by Kang et al. [30], applying HFNC in patients with re-
spiratory failure according to clinical response could lead
to delayed intubation. This could be associated with a
worse outcome, as has been shown with NIV. This may
be possible because HFNC increases comfort, oxygenation
and may disguise respiratory distress. The results by Her-
nandez et al. [1], reinforce this idea; under a fixed 24‐hour
protocol after extubation, the time to reintubation was not
increased, whether compared to conventional oxygen
therapy in the low‐risk‐of‐reintubation group or NIV in
the high‐risk‐of‐reintubation group. A 24‐h limit probably
helped physicians appreciate undertreated respiratory
distress at an early stage and not delay reintubation.
Nevertheless, the results confirmed that 24 h was enough
to reduce the rate of reintubation.
HFNC does not delay reintubation under those condi-
tions. This result can be attributed to the preventive
intention, the fixed duration and to the predefined rein-
tubation criteria.
Conclusion
Delivery of heated and humidified oxygen at high flow
rates through nasal cannulas is now widely used in
adult patients. Its mechanisms of action and potential
clinical benefits can help to improve the management
of patients with acute respiratory failure or during the
weaning phase. With the currently available evidence,
several questions still remain unanswered; there is
strong evidence for some clinical indications, but for
other situations without that evidence decisions on
HFNC treatment should be individualized in each par-
ticular situation and institution, taking into account
Hernández et al. Critical Care  (2017) 21:62 Page 10 of 11resources, and local and personal experience with all
respiratory support therapies. However, HFNC therapy
is an innovative and powerful technique that is
currently changing the management of patients with
respiratory failure.
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